首页> 外文期刊>The Journal of Nuclear Medicine >Improved detection of regional melanoma metastasis using 18F-6-fluoro-N-(2-(diethylamino)ethyl) pyridine-3-carboxamide, a melanin-specific PET probe, by perilesional administration.
【24h】

Improved detection of regional melanoma metastasis using 18F-6-fluoro-N-(2-(diethylamino)ethyl) pyridine-3-carboxamide, a melanin-specific PET probe, by perilesional administration.

机译:通过病灶周围给药,使用18F-6-氟-N-(2-(二乙氨基)乙基)吡啶-3-羧酰胺(一种黑色素特异性PET探针)改善了对局部黑色素瘤转移的检测。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The efficacy of differing routes of administration of 18F-6-fluoro-N-[2-(diethylamino)ethyl] pyridine-3-carboxamide (18F-MEL050), a new benzamide-based PET radiotracer for imaging regional lymph node metastasis in melanoma, was assessed. METHODS: B16-Black/6 metastatic melanoma cells harboring an mCherry transgene were implanted into the left-upper-foot surface of 49 C57 Black/6 mice as a model of popliteal lymph node (PLN) metastasis. Ultrasound scanning of the left PLN was performed at baseline and in combination with 18F-MEL050 PET on days 5, 9, and 14. Mice were divided into 2 groups to compare the results of tracer administration either subcutaneously at the tumor site (local) or in the lateral tail vein (systemic). After PET on each imaging day, 5 mice per group-including any with evidence of metastasis-were sacrificed for ex vivo validation studies including assessment of retained radioactivity and presence of the mCherry transgene as a surrogate of nodal tumor burden. RESULTS: Nine mice were judged as positive for PLN metastasis by ultrasound at day 5, and 8 PLNs were positive on 18F-MEL050 PET, 3 after systemic and 5 after local administration. Ex vivo analysis showed that ultrasound correctly identified 90% of positive PLNs, with 1 false-positive. 18F-MEL050 PET correctly identified 60% of positive PLNs after systemic administration and 100% after local administration with no false-positive results by either route. The average node-to-background ratio for positive PLNs was 6.8 in the systemic-administration group and correlated with disease burden. In the local-administration group, the mean uptake ratio was 48, without clear relation to metastatic burden. Additional sites of metastatic disease were also correctly identified by 18F-MEL050 PET. CONCLUSION: In addition to its potential for systemic staging, perilesional administration of 18F-MEL050 may allow sensitive and specific, noninvasive identification of regional lymph node metastasis in pigmented malignant melanomas.
机译:新型苯甲酰胺基PET放射性示踪剂18F-6-氟-N- [2-(二乙氨基)乙基]吡啶-3-羧酰胺(18F-MEL050)的不同给药途径对黑色素瘤区域淋巴结转移的显像,进行了评估。方法:将携带mCherry转基因的B16-Black / 6转移性黑素瘤细胞植入49只C57 Black / 6小鼠的左上脚表面,作为pop淋巴结转移的模型。在基线,并在第5、9和14天与18F-MEL050 PET结合对左PLN进行超声扫描。将小鼠分为两组,比较在肿瘤部位(局部)或皮下注射示踪剂的结果。在侧尾静脉(全身)。在每个成像日进行PET检查后,每组5只小鼠(包括任何具有转移证据的小鼠)被处死,用于离体验证研究,包括评估保留的放射性和mCherry转基因的存在,以作为淋巴结转移的替代指标。结果:在第5天,通过超声判断9只小鼠的PLN转移阳性,在18F-MEL050 PET上8只PLN阳性,全身给药3只,局部给药5只。离体分析显示,超声正确地识别了90%的阳性PLN,其中1个假阳性。 18F-MEL050 PET在全身给药后正确鉴定出60%的阳性PLN,在局部给药后正确鉴定出100%的PLN,无论哪种途径均没有假阳性结果。全身性给药组中阳性PLN的平均结点与背景之比为6.8,并与疾病负担相关。在局部给药组中,平均摄取率为48,与转移负担没有明显关系。 18F-MEL050 PET也可以正确识别其他转移性疾病部位。结论:除了可以进行全身分期外,病灶周围施用18F-MEL050还可以对色素性恶性黑色素瘤的区域淋巴结转移进行敏感,特异性,非侵入性的鉴定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号